Highlights•The CD19 paradigm has established CARs as a novel immunotherapy in
oncology.•The synthetic tool box is not limited to CARs and includes CCRs, iCARs and …

Advancement in our understanding of immune cell recognition and emerging cellular
engineering technologies during the last decades made active manipulation of the T cell …

Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T lymphocytes to
target chosen antigens. The targeting of CD19, a cell surface molecule expressed in the vast …

The focus of cancer treatment has recently shifted toward targeted therapies, including
immunotherapy, which allow better individualization of care and are hoped to increase the …

Introduction: Chimeric antigen receptors (CARs) usually combine the antigen binding site of
a monoclonal antibody with the signal activating machinery of a T cell, freeing antigen …

Chimeric antigen receptors (CARs) are versatile synthetic receptors that provide T cells with
engineered specificity. Clinical success in treating B-cell malignancies has demonstrated …

In the past 50 years, disease burden has steadily shifted from infectious disease to cancer.
Standard chemotherapy has long been the mainstay of cancer medical management, and …

Spearheaded by the therapeutic use of chimeric antigen receptors (CARs) targeting CD19,
synthetic immunology has entered the clinical arena. CARs are recombinant receptors for …

T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new
class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since …

Highlights•Description of structural elements of chimeric antigen receptors used to engineer
T cells.•Differences between T cell receptor and chimeric antigen receptor …